Your browser doesn't support javascript.
loading
Assessing Data Sources for Medicine Price Studies.
Vogler, Sabine; Schneider, Peter.
Affiliation
  • Vogler S; WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies,Pharmacoeconomics Department,Gesundheit Österreich GmbH (GÖG / Austrian Public Health Institute),Vienna,Austria.
  • Schneider P; WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies,Pharmacoeconomics Department,Gesundheit Österreich GmbH (GÖG / Austrian Public Health Institute),Vienna,Austria.
Int J Technol Assess Health Care ; 35(2): 106-115, 2019 Jan.
Article in En | MEDLINE | ID: mdl-30922418
OBJECTIVES: There is no established methodology to assess the feasibility of medicine price data sources. Against this backdrop, a framework to guide the selection of most appropriate price data sources for pharmacoeconomic research has been developed. METHODS: A targeted literature review was carried out. Dimensions discussed in literature as relevant for medicine price comparisons and practical experience of the authors in medicine price studies informed the conceptional work of the framework development. A draft version of the framework was reviewed by peer pricing experts. The feasibility of the framework was tested in case studies. RESULTS: According to the developed framework (called Re-ADAPT), a medicine price data source should meet the following criteria: reliability and sustainability; accessibility at a cost that users can afford; provision of medicine price information at the date(s) required; information for the defined geographic area, or at least in a representative way; coverage of the pharmaceuticals and at the price type(s) required. Easy handling and provision of additional information were defined as supportive assets of candidate data sources (secondary criteria). The case studies confirmed the feasibility of the Re-ADAPT framework. In some cases, however, it can be difficult to disentangle assessment criteria (particularly geographic area, scope of pharmaceuticals and price types) for separate consideration, given their interlinkage. CONCLUSIONS: While selection of the most appropriate data sources will remain a challenge, the Re-ADAPT framework aims to provide practical guidance and thus contribute to a more careful, balanced, and evidence-based selection of data sources for medicine price studies.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Technology Assessment, Biomedical / Economics, Pharmaceutical / Commerce / Prescription Drugs Type of study: Guideline / Health_economic_evaluation / Health_technology_assessment Limits: Humans Language: En Journal: Int J Technol Assess Health Care Journal subject: PESQUISA EM SERVICOS DE SAUDE Year: 2019 Document type: Article Affiliation country: Austria Country of publication: United kingdom

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Technology Assessment, Biomedical / Economics, Pharmaceutical / Commerce / Prescription Drugs Type of study: Guideline / Health_economic_evaluation / Health_technology_assessment Limits: Humans Language: En Journal: Int J Technol Assess Health Care Journal subject: PESQUISA EM SERVICOS DE SAUDE Year: 2019 Document type: Article Affiliation country: Austria Country of publication: United kingdom